Interestingly, treatment with miR‐183‐5p‐EVs led to a significant increase in the proportion of CD4+ and decrease in the proportion of CD8+ tumour‐infiltrating T lymphocytes (Figure 4j,k, Figure S8e) even though these cells did not incorporate the labeled‐miRNA EVs (Figure S9). The gene discussed is CD4; the disease is neoplasm.